Incorporating Human Relevant Stem-Cell Derived Cardiomyocytes in Drug Safety Studies: Inspirations and Future Aspirational Goals
Gary Gintant, Research Fellow, Abbvie
New applications for human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CM’s) continue to challenge users to define best uses for these cells and best practices for more comprehensive drug safety assessments. This presentation will discuss evolving uses for hiPSC-CMs involving inspirational cellular models and aspirational objectives in support of industrial in vitro cardiac safety screening and evaluations.
|
|
Add to Calendar ▼2018-10-04 00:00:002018-10-05 00:00:00Europe/LondonStem Cells in Drug Discovery and Toxicity Screening 2018Stem Cells in Drug Discovery and Toxicity Screening 2018 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
